Earnings Per Share

9 Months Ended

Sep. 30, 2024

Basic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023

Numerator:
Net loss attributable to Surgery Partners, Inc.	$	(31.7)	$	(4.9)	$	(59.6)	$	(10.9)



Denominator:
Weighted average common shares outstanding:
Basic	126,172		125,747		126,093		125,559
Diluted (1)	126,172		125,747		126,093		125,559

Net loss per share attributable to common stockholders:
Basic	$	(0.25)	$	(0.04)	$	(0.47)	$	(0.09)
Diluted (1)	$	(0.25)	$	(0.04)	$	(0.47)	$	(0.09)

Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:
Stock options	1,187		1,421		1,164		1,412
Restricted shares	281		208		264		202

(1)The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.